Medigen Biotechnology (Taiwan) Today
| 3176 Stock | TWD 35.40 0.05 0.14% |
PerformanceOK
| Odds Of DistressBelow Average
|
Medigen Biotechnology is selling for under 35.40 as of the 19th of March 2025; that is 0.14% down since the beginning of the trading day. The stock's lowest day price was 35.25. Medigen Biotechnology has about a 27 % chance of experiencing some form of financial distress in the next two years of operation and did not have a very good performance during the last 90 trading days. The performance scores are derived for the period starting the 19th of December 2024 and ending today, the 19th of March 2025. Click here to learn more.
Moving together with Medigen Stock
Moving against Medigen Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Medigen Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Medigen Biotechnology's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Medigen Biotechnology or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Thematic Idea | Biotech (View all Themes) |
| Business Concentration | Biotech, Health Care, Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care (View all Sectors) |
Medigen Biotechnology (3176) is traded on Taiwan OTC Exchange in Taiwan and employs 18 people. The company currently falls under 'Mid-Cap' category with a current market capitalization of 4.42 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Medigen Biotechnology's market, we take the total number of its shares issued and multiply it by Medigen Biotechnology's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Medigen Biotechnology operates under Biotechnology sector and is part of Health Care industry. The entity has 139.45 M outstanding shares.
Medigen Biotechnology generates positive cash flow from operations, but has no cash available
Check Medigen Biotechnology Probability Of Bankruptcy
Ownership AllocationMedigen Biotechnology maintains a total of 139.45 Million outstanding shares. Medigen Biotechnology holds significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Medigen Ownership Details
Medigen Biotechnology Risk Profiles
Although Medigen Biotechnology's alpha and beta are two of the key measurements used to evaluate Medigen Biotechnology's performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 1.32 | |||
| Semi Deviation | 1.65 | |||
| Standard Deviation | 2.16 | |||
| Variance | 4.68 |
Medigen Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Medigen Biotechnology without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Price Transformation Now
Price TransformationUse Price Transformation models to analyze the depth of different equity instruments across global markets |
| All Next | Launch Module |
Medigen Biotechnology Corporate Executives
Elected by the shareholders, the Medigen Biotechnology's board of directors comprises two types of representatives: Medigen Biotechnology inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Medigen. The board's role is to monitor Medigen Biotechnology's management team and ensure that shareholders' interests are well served. Medigen Biotechnology's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Medigen Biotechnology's outside directors are responsible for providing unbiased perspectives on the board's policies.
Additional Tools for Medigen Stock Analysis
When running Medigen Biotechnology's price analysis, check to measure Medigen Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Medigen Biotechnology is operating at the current time. Most of Medigen Biotechnology's value examination focuses on studying past and present price action to predict the probability of Medigen Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Medigen Biotechnology's price. Additionally, you may evaluate how the addition of Medigen Biotechnology to your portfolios can decrease your overall portfolio volatility.